Internal Medicine, Medical Oncology · Shiloh, IL
NPI
1033167846
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1418 Cross St, Div Im Medical Oncology, Ste 180
Shiloh, IL, 62269
Phone (618) 607-1340
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.5M
186,982 services
Medicare patients, 2024
693
Average age 74
Drug cost, 2024
$9.1M
5,918 prescriptions
Company payments, 2025
$45.13
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John L Visconti was code J9271 (injection, pembrolizumab, 1 mg), 17,800 times for 24 patients. In total John L Visconti billed 186,982 services in 144 codes, and Medicare paid $3.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 17,800 | 24 | $44.41 | $790K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 15,750 | 14 | $0.87 | $14K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 12,270 | 13 | $2.26 | $28K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 9,300 | 17 | $0.10 | $961 |
| J0897 Injection, denosumab, 1 mg | Office | 8,520 | 35 | $19.75 | $168K |
| J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 3,900 | 23 | $38.50 | $150K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,130 | 81 | $0.09 | $284 |
| Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 3,110 | 14 | $26.03 | $81K |
| Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 2,420 | 11 | $20.50 | $50K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,710 | 52 | $0.79 | $1,352 |
| 99213 Office E&M - Established | Office | 1,172 | 430 | $68.49 | $80K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 973 | 17 | $3.69 | $3,594 |
| J2506 Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 732 | 25 | $64.53 | $47K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 730 | 21 | $0.27 | $196 |
| J9190 Injection, fluorouracil, 500 mg | Office | 654 | 17 | $2.43 | $1,592 |
By year: 2022 $2.9M for 185,787 services; 2023 $5.9M for 332,491 services; 2024 $3.5M for 186,982 services.
Medicare prescription drug claims, 2024
In 2024, the drug John L Visconti prescribed most often to Medicare patients was Anastrozole, with 360 prescriptions and refills. In total John L Visconti wrote 5,918 Medicare prescriptions that cost $9.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 360 | 878 | 112 | $3,893 |
| Prednisone Generic | 355 | 409 | 101 | $2,040 |
| Ondansetron Hcl Generic | 279 | 296 | 134 | $1,975 |
| Gabapentin Generic | 259 | 396 | 74 | $4,391 |
| Pantoprazole Sodium Generic | 239 | 508 | 104 | $1,892 |
| Tamoxifen Citrate Generic | 230 | 565 | 66 | $4,221 |
| Dexamethasone Generic | 226 | 238 | 77 | $2,788 |
| Letrozole Generic | 145 | 361 | 49 | $2,508 |
| Abiraterone Acetate Generic | 137 | 139 | 20 | $126K |
| Eliquis Apixaban | 116 | 133 | 28 | $79K |
| Hydroxyurea Generic | 116 | 186 | 23 | $1,877 |
| Xtandi Enzalutamide | 105 | 105 | 19 | $1.5M |
| Oxycodone Hcl Generic | 102 | 102 | 26 | $1,555 |
| Metoclopramide Hcl Generic | 100 | 103 | 46 | $592 |
| Methylphenidate Hcl Generic | 98 | 98 | 29 | $1,489 |
Brand drugs: - claims; generic drugs: 5,020 claims; opioid claims: 490.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John L Visconti $45.13 ($45.13 in general payments such as food, travel and fees) from 1 company. The largest payer was EMD Serono, Inc. with $45.13.
| Company | Payments | Amount |
|---|---|---|
| EMD Serono, Inc. MRK.DE | 2 | $45.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.